Negative phase 3 study of Y-90 microspheres versus sorafenib in HCC

Etienne Garin (1, 2) , Yan Rolland (3, 2) , Boris Campillo-Gimenez (2, 3) , Julien Edeline (1, 2)

1 NuMeCan - Nutrition, Métabolismes et Cancer
2 CRLCC - CRLCC Eugène Marquis
3 LTSI - Laboratoire Traitement du Signal et de l'Image

Correspondence: It is with great interest that we read the report of the SARAH trial by Valérie Vilgrain and colleagues, recently published The Lancet Oncology...

Domaines: Ingénierie biomédicale

Etienne Garin, Yan Rolland, Boris Campillo-Gimenez, Julien Edeline. Negative phase 3 study of Y-90 microspheres versus sorafenib in HCC. Lancet Oncology, 2018, 19 (2), pp.e69. ⟨10.1016/S1470-2045(18)30025-1⟩. ⟨hal-01709600⟩